TRCT
ARIA

Tower Research Capital (TRC)’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18,005
Closed -$224K – 4572
2016
Q4 		$224K Buy
18,005
+17,545
+3,814% +$211K 0.02% 588
2016
Q3 		$6K Buy
+460
New +$4.62K ﹤0.01% 2501
2016
Q2 		– Sell
-2,916
Closed -$19K – 5417
2016
Q1 		$19K Buy
+2,916
New +$16.3K ﹤0.01% 1406
2015
Q4 		– Sell
-25,017
Closed -$146K – 5525
2015
Q3 		$146K Buy
25,017
+11,913
+91% +$91.8K 0.01% 394
2015
Q2 		$108K Sell
13,104
-36,044
-73% -$319K 0.01% 744
2015
Q1 		$405K Buy
49,148
+48,648
+9,730% +$360K 0.05% 199
2014
Q4 		$3K Buy
+500
New +$3.13K ﹤0.01% 3231
2014
Q2 		– Sell
-2,153
Closed -$14.8K – 5068
2014
Q1 		$17K Sell
2,153
-14,851
-87% -$116K ﹤0.01% 2085
2013
Q4 		$116K Buy
+17,004
New +$91.8K 0.02% 784

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Tower Research Capital (TRC)'s ARIA Position: Q1 2017 in Review

Tower Research Capital (TRC) sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 18,005 shares — an estimated $224K sold.

Tower Research Capital (TRC) first reported a position in ARIA in Q4 2013 and held it in 9 quarters. The position peaked at $405K in Q1 2015. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Tower Research Capital (TRC) reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 18,005 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $224K.
  • Tower Research Capital (TRC) first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s Ariad Pharmaceuticals Inc position peaked at $405K in Q1 2015.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2017, filed 19 May 2017.